Aspira pathlab & Diagnostics Limited has formally notified BSE Limited of its non-applicability under the Large Corporate framework as defined by SEBI regulations. The Mumbai-based diagnostic services company submitted its compliance confirmation on April 15, 2026, addressing requirements under SEBI Circular SEBI/HO/DDHS/CIR/P/2018/144.

Regulatory Compliance Status

The company confirmed its status as of March 31, 2026, through a detailed submission to the Corporate Relations Department of BSE Limited. Chief Financial Officer Balkrishna Talawadekar signed the compliance document, ensuring adherence to regulatory disclosure requirements.

Financial Position Details

The company's financial status as of March 31, 2026, demonstrates its position outside the Large Corporate classification criteria:

SEBI Framework Implications

Under SEBI Circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018, companies meeting specific criteria must comply with enhanced regulations for debt securities issuance. Aspira Pathlab's confirmation indicates it falls outside these parameters, exempting it from the framework's requirements.

Company Background

Aspira Pathlab & Diagnostics Limited operates as a fully integrated diagnostic laboratory service provider. The company maintains its registered office in Ghatkopar West, Mumbai, and positions itself as India's first fully integrated lab facility. The organization provides comprehensive diagnostic services under the tagline "Predict • Prevent • Protect."

Regulatory Documentation

The company submitted Annexure A as required under the SEBI circular, providing complete details of its corporate structure and financial position. This documentation serves as official confirmation of its non-Large Corporate status and ensures compliance with regulatory disclosure obligations for the assessment period ending March 31, 2026.

Aspira pathlab & Diagnostics Limited has filed its mandatory compliance certificate with BSE Limited for the quarter ended March 31, 2026. The submission, dated April 14, 2026, fulfills the company's regulatory obligations under SEBI (Depositories and Participants) Regulations, 2018.

Regulatory Compliance Filing

The compliance certificate was submitted pursuant to regulation 74(5) of the SEBI (Depositories and Participants) regulations, 2018. The document was signed by Pankaj Shah, Managing Director of Aspira Pathlab & Diagnostics Limited, and forwarded to the Listing Department of BSE Limited.

Registrar Confirmation

MUFG Intime India Private Limited, formerly known as Link InTime India Private Limited, serves as the company's Registrar & Share Transfer Agent. The firm issued the compliance certificate on April 3, 2026, confirming adherence to prescribed procedures for handling dematerialised securities.

The registrar's certificate confirms several key compliance aspects:

• Securities received from depository participants for dematerialisation during the quarter were properly confirmed to depositories
• All securities comprised in certificates have been listed on stock exchanges where earlier issued securities are listed
• Security certificates received for dematerialisation were confirmed or rejected within prescribed timelines
• Received certificates were mutilated and cancelled after due verification by depository participants
• Names of depositories were substituted in the register of members as registered owners

Company Information

Aspira Pathlab & Diagnostics Limited operates with its registered office located at Flat No. 2, R D Shah Building, Shraddhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai-400086. The company's corporate office is situated at 6 & 7, Bhaveshwar Arcade, Near Shreyas Junction LBS Marg, Behind Saraswat Bank, Ghatkopar (W), Mumbai-400086.

The filing represents routine regulatory compliance, ensuring transparency and proper governance in the handling of shareholder securities and maintaining adherence to SEBI guidelines for depositories and participants.